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Abstract
Systemic lupus erythematosus (SLE) is a pervasive disease with wide-ranging effects on physical, psychological and social
well-being. As such, a comprehensive assessment of SLE should include several different outcomes, such as quality of life
(QoL) and economic costs, in addition to measures of disease activity and damage. In fact, disease effects on QoL are often
considered of greater overall importance to patients. Two approaches have been used in the measurement of QoL: generic
questionnaires and disease-speciﬁc questionnaires. Generic questionnaires are designed to be used across various conditions
and populations, whereas disease-speciﬁc questionnaires are designed to measure outcomes in one speciﬁc disease or
condition. The most commonly used measure of QoL is the Medical Outcomes Study Short Form 36 (SF-36), which is a
generic measure that is applicable in a variety of conditions, including SLE. Recently, SLE-speciﬁc measures have been
developed that may prove to be more responsive than generic measures. The hope is that improved outcome measures will
allow for better assessment of SLE and eventually facilitate drug development and improve patient care.
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Introduction
SLE is a pervasive disease that results in variable and
occasionally life-threatening, manifestations. It afﬂicts
youngpeopledisproportionately,oftenatacrucialtime
in their lives when they are trying to establish
relationships, start families and launch careers. As a
result, persons with SLE may experience a wide range
of physical, psychological and social problems that are
not always fully captured by descriptions of the
disease’s physiological consequences alone. In order
tocharacterizethefullspectrumoftheeffectsofSLE,a
comprehensive assessment should consider avarietyof
other outcomes, which may be of equal or even greater
importance to the patient. One such outcome is QoL,
which is increasingly being recognized as an important
aspect of chronic diseases and considered by many as a
relevant measure of efﬁcacy in clinical trials.
Outcome measures used in SLE
The course of SLE is characterized by exacerbations
(or ﬂares) of disease activity and disease damage.
Disease damage is permanent and may result from
repeated ﬂares of disease activity, or as a result of
adverse effects of treatments or other co-morbidities.
Measures of disease activity include the systemic lupus
activity measure-revised (SLAM-R) (Bae et al. 2001),
the SLEdiseaseactivityindex(SLEDAI) (Bombardier
et al. 1992) and the British Isles Lupus Assessment
Group (BILAG) disease activity index (Stoll et al.
1996). Disease damage is most often measured
through the Systemic Lupus International Collaborat-
ing Clinics/American College of Rheumatology
Damage Index (SLIC/ACR DI) (Gladman et al.
1996, 1997). However, in addition to disease activity
and damage, there are other important consequences
of disease that include changes in QoL, employment
and social functioning. Therefore, in an effort to
improve assessment of outcomes in SLE, the outcome
measuresinrheumatologyclinicaltrials(OMERACT)
group has recommended that trials of SLE include
outcome measures of QoL, adverse events and
economic costs, in addition to measures of disease
activity and disease damage (Strand et al. 2000).
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QoL and more speciﬁcally, HRQoL refers to the
impact that a disease and its treatment has on an
individual’s ability to function and his or her perceived
well-being in physical, mental and social domains of
life. Increasing pressure on the use of health care
resources has resulted in a need for measures that will
best assess the relative effectiveness and appropriate-
ness of rival medical treatments. Measurement of
HRQoL, in addition to more objective clinical
indicators of disease, allows for a more comprehensive
assessment and in some cases may prove to be a more
sensitive indicator of treatment response than
measures of disease activity or damage (Strand et al.
2003). Furthermore, information about broader
patient outcomes, including outcomes of importance
to patients, helps physicians and patients when
making decisions about the most appropriate health
care. The challenge remains to identify instruments
that will accurately and reliably assess these disease
outcomes.
Measurement of HRQoL has traditionally relied on
two basic approaches: the use of generic questionnaires
and the use of disease-speciﬁc questionnaires. Generic
questionnaires were developed for general use and
may be used in a variety of diseases and populations.
They allow for comparison with other groups and
other conditions and allow measurement of dysfunc-
tion for individuals experiencing more than one
condition. In contrast, disease-speciﬁc questionnaires
are designed to measure outcomes in a speciﬁc
disease. Because they incorporate elements speciﬁc to
particular diseases, they are believed to be more
responsive than generic instruments. Only recently
have disease-speciﬁc instruments been developed for
use in SLE and these are not yet in wide use.
Generic measures (Table I)
At present, the most commonly used measure of
HRQoL is the SF-36. Developed by Ware et al.
(1992), the SF-36 is a generic, 36-item self-report
questionnaire designed to be used in a variety of
conditions, populations, and settings. It includes eight
subscales (physical functioning, social functioning,
role limitations due to physical problems, role
limitations due to emotional problems, mental health,
energy/vitality, pain and general health perception)
that can be summarized into two component scores:
the physical component summary score and the
mental component summary score. The SF-36 has
been shown to be a valid and reliable instrument in
SLE (Stoll et al. 1997) and has been used in numerous
studies in SLE. Using the SF-36, several studies have
demonstrated that persons with SLE have a signiﬁ-
cantly poorer QoL than persons without a chronic
illness (Stoll et al. 1997; Sutcliffe et al. 1999).
Other generic HRQoL questionnaires that have
been used in SLE include the European QoL scale
(EQ-5D) (The EuroQol Group 1990; Kind 1996),
the World Health Organization quality of life scale
(WHOQOL-Bref) (The WHOQOL Group 1998), the
Nottingham health proﬁle (NHP) (Hunt et al. 1981)
and the sickness impact proﬁle (SIP) (Bergner et al.
1981). The EQ-5D is a simple measure that assesses
ﬁve dimensions of health status: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depres-
sion. Wang et al. (2001) in a study of 54 persons with
SLE, showed the EQ-5D to be a valid instrument for
the measurement of HRQoL. Luo et al. (2003a,b)
have shown both a Singaporean English and a
Singaporean Chinese version of the EQ-5D to be
valid in persons with various rheumatic diseases,
including SLE. The WHOQOL-Bref, a 26 item
questionnaire assessing four domains of QoL (physi-
cal, psychological, social and environmental) was
evaluated in 73 patients from India (Khanna et al.
2004). Only the physical and psychological domains
of QoL were found to be impaired in patients with
active SLE. The NHP and the SIP have been used in a
varietyof diseases; however, neither has beenvalidated
in SLE.
Disease-speciﬁc measures
The Stanford health assessment questionnaire (HAQ)
(Fries et al. 1980) was initially developed for use in
persons with arthritis and has become the most
commonly used measure of functioning in the
rheumatic diseases, particularly rheumatoid arthritis.
Although initially developed to assess the impact of
arthritis, it has been used and validated in a variety of
other conditions and thus may also be regarded as a
generic instrument. The HAQ is a 20-item ques-
tionnaire that assesses activities of daily living in eight
domains: dressing, arising, eating, walking, hygiene,
reaching, gripping and errands and chores. Although
it has been shown to be a valid instrument for use in
SLE (Hochberg and Sutton 1988; Milligan et al.
1993), an important limitation is that it only assesses
physical functioning. Therefore, for a more compre-
hensive assessment, it should be used in combination
with instruments that also assess psychosocial
functioning.
Another instrument that was developed for use
mainly in persons with arthritis is the arthritis impact
measurement scale (AIMS) (Meenan et al. 1982),
which was revised in 1992 (AIMS2) (Meenan et al.
1992). It is a 78-item questionnaire that assesses
physical functioning, activities of daily living, social
activities, social support, arthritis pain, work, level of
tension, mood, satisfaction with health, general health
perceptions, overall impact of arthritis and medi-
cations. In SLE, the AIMS has been used in only one
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toid arthritis (Burckhardt et al. 1993).
SLE-speciﬁc measures
Three disease-speciﬁc QoL measures have been
recently developed for use in SLE.
Leong et al. (2005) developed and validated a new
40-item SLE-speciﬁc QoL instrument, the systemic
lupus erythematosus-speciﬁc quality-of-life (SLE-
QOL). The questionnaire consists of 6 subsections:
physical functioning, activities, symptoms, treatment,
mood and self-image. It was evaluated in 275 persons
with SLE and was found to be more responsive to
change than the SF-36. It was shown to be valid,
possessing construct validity, face and content validity,
internal consistency, test–retest reliability and respon-
siveness. Another SLE-QoL questionnaire was
recently developed by Grootscholten et al. (2003)
the SSC. Testing for reliability and reproducibility has
shown satisfactory internal consistency and test–
retest reliability. A third SLE-speciﬁc measure
of HRQoL is the Lupus QoL Scale (LupusQoL)
(Teh et al. 2005). This is a 34-item questionnaire that
assesses 8 domains: physical functioning, pain,
emotional functioning, fatigue, body image, sex,
planning and burden to others. It possesses internal
consistency, test–retest reliability and concurrent
validity when compared with the SF-36.
The development of these SLE-speciﬁc instruments
may prove to be invaluable in SLE drug trials, which
have suffered from a lack of sensitive outcome
measures that are able to detect clinically meaningful
differences between competing therapeutic strategies.
These questionnaires may prove to be more responsive
in certain situations and may address issues of
particular concern in persons with SLE. Nevertheless,
they will require further evaluation before they can
be recommended for routine use. Furthermore,
although there are advantages to using disease-speciﬁc
questionnaires, the current general consensus is that
generic measures should be used preferentially,
supplemented with disease-speciﬁc measures where
applicable.
Conclusion
The various questionnaires described above have been
used in the assessment of a number of diseases,
including SLE. Each has its own advantages and
disadvantages and the choice of which measure to use
should be made on an individual basis, taking into
consideration the speciﬁc aims of the study. Generic
measures are widely used and have the advantage of
allowing comparisons between different conditions.
The SF-36, in particular, is currently the preferred
outcome measure for HRQoL in US health policy
research. It has also proven to be more responsive than
measures of disease activity in at least one clinical trial
of a novel therapeutic agent for SLE, LPJ-394 (Strand
et al. 2003). The hope is that newly developed SLE-
speciﬁc questionnaires will be even more responsive,
so as to better assess the efﬁcacy of current and new
therapeutic agents. No new drug has been approved
for the treatment of SLE in over 25 years. This failure
to demonstrate beneﬁt may be at least partly due to a
lack of appropriate outcome measures. Better
measures of HRQoL, in combination with improved
measures of disease activity and disease damage, will
help drive the development of new therapeutic agents
and facilitate their approval.
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